UNCY: Unicycive Therapeutics, Inc. Stock

by  •  • Comments Off on UNCY: Unicycive Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 42.12
Enterprise Value ($M) 32.42
Book Value ($M) -3.81
Book Value / Share -0.10
Price / Book -11.06
NCAV ($M) -4.60
NCAV / Share -0.12
Price / NCAV -9.15

Profitability (mra)
Return on Invested Capital (ROIC) n/a
Return on Assets (ROA) -1.12
Return on Equity (ROE) -2.90

Liquidity (mrq)
Quick Ratio 0.76
Current Ratio 0.76

Balance Sheet (mrq) ($M)
Current Assets 13.40
Assets 14.19
Liabilities 18.00
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.68
Operating Income -20.77
Net Income -30.54

Cash Flow Statement (mra) ($M)
Cash From Operations -18.28
Cash from Investing -0.01
Cash from Financing 27.54

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A Armistice Capital, Llc 2.73 0.00
02-14 13G/A Nantahala Capital Management, LLC 9.90 187.86
02-14 13G/A Ra Capital Management, L.p. 9.99 0.04
02-05 13G Nantahala Capital Partners Limited Partnership 6.10 0.00
01-22 13G Logos Global Management LP 9.90
07-14 13G Vivo Opportunity Fund Holdings, L.P. 9.99
07-06 13G Biotechnology Value Fund L P 9.99

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI
2023-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT
2023-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S
2023-05-16 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-03 51,593 166,112 31.06
2024-05-02 65,655 30,705 213.83
2024-05-01 103,944 58,385 178.03
2024-04-30 156,838 109,059 143.81
2024-04-29 534,265 248,424 215.06

(click for more detail)

Similar Companies
TRAW – Traws Pharma, Inc. TRVN – Trevena, Inc.
TTNP – Titan Pharmaceuticals, Inc. UPC – Universe Pharmaceuticals INC
UPXI – Upexi, Inc.


Financial data and stock pages provided by
Fintel.io